ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
2.680
+0.030 (1.13%)
At close: May 22, 2025, 4:00 PM
2.700
+0.020 (0.75%)
After-hours: May 22, 2025, 7:41 PM EDT
ImmunityBio Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for ImmunityBio stock ranges from a low of $5.00 to a high of $30. The average analyst price target of $11.4 forecasts a 325.37% increase in the stock price over the next year.
Price Target: $11.40 (+325.37%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ImmunityBio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 3 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $4.25 → $5 | Hold → Buy | Upgrades | $4.25 → $5 | +86.57% | May 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +198.51% | May 12, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +1,019.40% | May 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +198.51% | Apr 28, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +1,019.40% | Apr 28, 2025 |
Financial Forecast
Revenue This Year
100.12M
from 14.75M
Increased by 579.01%
Revenue Next Year
273.94M
from 100.12M
Increased by 173.61%
EPS This Year
-0.50
from -0.62
EPS Next Year
-0.28
from -0.50
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 130.2M | 353.1M | 1.3B | ||
| Avg | 100.1M | 273.9M | 648.8M | ||
| Low | 83.7M | 181.7M | 353.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 783.0% | 252.7% | 359.6% | ||
| Avg | 579.0% | 173.6% | 136.8% | ||
| Low | 467.5% | 81.4% | 28.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.44 | -0.23 | 0.54 | ||
| Avg | -0.50 | -0.28 | 0.08 | ||
| Low | -0.57 | -0.33 | -0.11 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.